Drug Manufacturers - Major Industry
Sector
Related Industries
Stocks in Drug Manufacturers - Major Sector
A.P. Pharma Inc.
AbbVie Inc.
ALUMIFUEL PWR CORP.
Bristol-Myers Squibb Company
China Pharma Holdings
GlaxoSmithKline plc
HST GLOBAL
ImmunoBiotics, Inc.
Intercept Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc.
Kythera Biopharmaceuticals, Inc.
Merck & Co. Inc.
Neutra Corp.
Novogen
Pfizer
QUICK-MED TECHNOLOG
Rigel Pharmaceuticals
Skystar Bio-Pharmaceutical Company
Spectrum Pharmaceuticals
TONGLI PHARMA USA
Wuxi Pharmatech (Cayman)
Zoetis Inc.
AbbVie Inc.
ALUMIFUEL PWR CORP.
Bristol-Myers Squibb Company
China Pharma Holdings
GlaxoSmithKline plc
HST GLOBAL
ImmunoBiotics, Inc.
Intercept Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc.
Kythera Biopharmaceuticals, Inc.
Merck & Co. Inc.
Neutra Corp.
Novogen
Pfizer
QUICK-MED TECHNOLOG
Rigel Pharmaceuticals
Skystar Bio-Pharmaceutical Company
Spectrum Pharmaceuticals
TONGLI PHARMA USA
Wuxi Pharmatech (Cayman)
Zoetis Inc.
Abbott Laboratories
Aceto Corporation
Bionovo, Inc.
CALLISTO PHARMACTLS
Eli Lilly and Company
HEALTHSPORT
Hubei Minkang Pharmaceutical Ltd
Impax Laboratories
Johnson & Johnson
Keryx Biopharmaceuticals
MEDIZONE INTL
Myriad Pharmaceuticals
Novartis AG
Omeros
PROVECTUS PHARMA
Regulus Therapeutics Inc.
Sanofi-Aventis SA
Soul and Vibe Interactive Inc.
THRIVE WORLD WIDE
VERTICAL HEALTH COM
ZNOMICS
Aceto Corporation
Bionovo, Inc.
CALLISTO PHARMACTLS
Eli Lilly and Company
HEALTHSPORT
Hubei Minkang Pharmaceutical Ltd
Impax Laboratories
Johnson & Johnson
Keryx Biopharmaceuticals
MEDIZONE INTL
Myriad Pharmaceuticals
Novartis AG
Omeros
PROVECTUS PHARMA
Regulus Therapeutics Inc.
Sanofi-Aventis SA
Soul and Vibe Interactive Inc.
THRIVE WORLD WIDE
VERTICAL HEALTH COM
ZNOMICS
Drug Manufacturers - Major Upgrades
Drug Manufacturers - Major Downgrades
Drug Manufacturers - Major New Coverages
Drug Manufacturers - Major Earnings
Date
Company
Actual
Expected
Prev Yr Qtr
Special Offers
On This Date
February 8, 2000:
Pfizer confirms it will pay $93.4 billion to buy Warner-Lambert, thereby creating the world's No. 2 drug firm with $28 billion in revenue and $4.7 billion in annual R&D spending.
Pfizer confirms it will pay $93.4 billion to buy Warner-Lambert, thereby creating the world's No. 2 drug firm with $28 billion in revenue and $4.7 billion in annual R&D spending.
